Immunoglobulin E in primary immunodeficiency diseases

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 57, Issue 11, 2002, Pages 995-1007

  Grimbacher, B ^a   Belohradsky, B H ^b   Holland, S M ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Hyper IgE syndrome; Immunoglobulin E; Netherton Com l syndrome; Omenn syndrome; Primary immunodeficiency; Wiskott Aldrich syndrome

Indexed keywords

IMMUNOGLOBULIN E;

DRUG BLOOD LEVEL; HUMAN; HYPERIMMUNOGLOBULINEMIA E; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; MAJOR HISTOCOMPATIBILITY COMPLEX; NETHERTON DISEASE; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR UPREGULATION; REVIEW; WISKOTT ALDRICH SYNDROME;

CHILD; CHILD WELFARE; CHILD, PRESCHOOL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOGLOBULIN E; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; INFANT WELFARE; INFANT, NEWBORN; MALE; METABOLISM, INBORN ERRORS;

EID: 0036829786     PISSN: 01054538     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1398-9995.2002.02168.x     Document Type: Review

References (139)

1. Ishizaka K, Ishizaka T. Hornbrook MM. Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol 1966;97:75-85.
2. Bennich H. WHO Immunoglobulin Reference Center official report. Bull World Health Org 1968,151-152.
3. Kulig M, Tacke U, Forster J, et al. Serum IgE levels during the first 6 years of life. J Pediatr 1999;134:453-458.
4. Johansson SG, Hourihane J O'B, Bousquet J, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001;56:813-824.
5. Oettgen HC. Geha RS. IgE in asthma and atopy: cellular and molecular connections. J Clin Invest 1999;104:829-835.
6. Yamaguchi M, Lantz CS, Oettgen HC, et al. IgE enhances mouse mast cell Fc (epsilon) RI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions. J Exp Med 1997;185:663-672.
7. Williams CM, Galli SJ. The diverse potential effector and immunoregulatory roles of mast cells in allergic disease. J Allergy Clin Immunol 2000;105:847-859.
8. Paul WE, Ohara J. B-cell stimulatory factor-1/interleukin-4. Ann Rev Immunol 1987;5:429-459.
9. De Vries JE, Punnonen J, Cocks BG, De Waal MR, Aversa G. Regulation of the human IgE response by IL4 and IL13. Res Immunol 1993;144:597-601.
10. Punnonen J, Aversa G, Cocks BG, et al. Interleukin-13 induces interleukin-4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 1993;90:3730-3734.
11. McKenzie AN, Culpepper JA, De Waal MR, et al. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci USA 1993;90:3735-3739.
12. Levy DA, Chen J. Healthy IgE-deficient person. N Engl J Med 1970;283:541-542.
13. Gardulf A, Andersen V, Bjorkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: Safety and costs. Lancet 1995;345:365-369.
14. Anwar AR, Smithers SR, Kay AB. Killing of schistosomula of Schistosoma mansoni coated with antibody and/ or complement by human leukocytes in vitro: Requirement for complement in preferential killing by eosinophils. J Immunol 1979;122:628-637.
15. Capron M, Bazin H, Joseph M, Capron A. Evidence for IgE-dependent cytotoxicity by rat eosinophils. J Immunol 1981;126:1764-1768.
16. Juhlin L, Michaelsson G. A new syndrome characterised by absence of eosinophils and basophils. Lancet 1977;1:1233-1235.
17. Kairemo KJ, Lindberg M, Prytz M. IgE myeloma: A case presentation and a review of the literature. Scand J Clin Laboratory Invest 1999;59:451-456.
18. Ohman S, Johansson SG. Allergen-specific IgE in atopic dermatitis. Acta Derm Venereol 1974;54:283-290.
19. Nordbring F, Johansson SG. IgM in cytomegalovirus mononucleosis. Scand J Infect Dis 1971;3:87-90.
20. Cederqvist LL, Francis LC, Zervoudakis IA, Becker CG. Litwin SD. Fetal immune response following prematurely ruptured membranes. Am J Obstet Gynecol 1976;126:321-327.
21. Gerrard JW, Heiner DC, Ko CG, Mink J, Meyers A, Dosman JA. Immunoglobulin levels in smokers and non-smokers. Ann Allergy 1980;44:261-262.
22. Ringden O, Persson U, Johansson SGO, et al. Markedly elevated serum IgE levels following allogeneic and syngeneic bone marrow transplantation. Blood 1983;61:1190-1195.
23. Coffman RL, Carty J. A T cell activity that enhances polyclonal IgE production and its inhibition by interferon-gamma. J Immunol 1986;136:949-954.
24. Bergstedt-Lindqvist S, Moon HB, Persson U, Moller G, Heusser C, Severinson E. Interleukin 4 instructs uncommitted B lymphocytes to switch to IgG1 and IgE. Eur J Immunol 1988;18:1073-1077.
25. Driscoll DA, Sullivan KE. DiGeorge syndrome: a chromosome 22q11.2 deletion syndrome. In: OCHS HD, Smith CIE, PUCK JM, editors. Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. New York, Oxford: Oxford University Press 1999, 198-208.
26. Belohradsky. Ergebnisse der Inneren Medizin und Kinderheilkunde. Thymusaplasie und -Hypoplasie Mit Hypoparathyreoidismus, Herz- und Gefäßmißbildungen (Di-George-Syndrom). Berlin Heidelberg: Springer-Verlag 1985, 36-105.
27. Kikkawa Y, Kamimura K, Hamajima T, Sekiguchi T, Kawai T. Thymic alymphoplasia with hyper-IgE-globulinemia. Pediatrics 1973;51:690-696.
28. Polmar SH, Waldmann TA, Terry WD. IgE in immunodeficiency. Am J Pathol 1972;69:499-512.
29. Hayakawa H, Iwata T, Yata J, Kobayashi N. Primary immunodeficiency syndrome in Japan. I. Overview of a nationwide survey on primary immunodeficiency syndrome. J Clin Immunol 1981;1:31-39.
30. Newcomb RW, Ishizaka K. Skin reactions to anti-gamma E antibody in atopic, nonatopic, and immunologically deficiency children and adults. J Allergy 1969;43:292-300.
31. Lischner HW, Huff DS. T-cell deficiency in DiGeorge syndrome. Birth Defects Orig Art Series 1975;11:16-21.
32. Buckley RH, Fiscus SA. Serum IgD and IgE concentrations in immunodeficiency diseases. J Clin Invest 1975;55:157-165.
33. Davis SD, Schaller J, Wedgwood RJ. Job's syndrome: Recurrent, 'cold', staphylococcal abscesses. Lancet 1966;1:1013-1015.
34. Buckley RH, Wray BB, Belmaker EZ. Extreme hyperimmunoglobulinemia E and undue susceptibility to infection. Pediatrics 1972;49:59-70.
35. Hill HR, Quie PG. Raised serum-IgE levels and defective neutrophil chemotaxis in three children with eczema and recurrent bacterial infections. Lancet 1974;1:183-187.
36. Grimbacher B, Holland SM, Gallin JI, et al. Hyper-IgE syndrome with recurrent infections - An autosomal dominant multisystem disorder. N Engl J Med 1999;340:692-702.
37. Donabedian H, Gallin JI. Two inhibitors of neutrophil chemotaxis are produced by hyperimmunoglobulin E recurrent infection syndrome mononuclear cells exposed to heat-killed staphylococci. Infect Immun 1983;40:1030-1037.
38. Belohradsky BH, Daumling S, Kiess W, Griscelli C. The hyper- syndrome (Buckley or Job syndrome) Ergeb Inn Med Kinderheilkd 1987;55:1-39.
39. Erlewyn-Lajeunesse MD. Hyperimmunoglobulin-E syndrome with recurrent infection: a review of current opinion and treatment. Pediatr Allergy Immunol 2000;11:133-141.
40. Van Scoy RE, Hill HR, Ritts RE, Quie PG. Familial neutrophil chemotaxis defect, recurrent bacterial infections, mucocutaneous candidiasis, and hyperimmunoglobulinemia E. Ann Intern Med 1975;82:766-771.
41. Buckley RH. Disorders of the IgE System. In Stiehm ER, editor: Immunologic Disorders in Infants and Children. Philadelphia: Saunders 1996, 409-422.
42. Blum R, Geller G, Fish LA. Recurrent severe staphylococcal infections, eczematoid rash, extreme elevations of IgE, eosinophilia, and divergent chemotactic responses in two generations. J Pediatr 1977;90:607-609.
43. Leung DY, Geha RS. Clinical and immunologic aspects of the hyperimmunoglobulin E syndrome. Hematol Oncol Clin North Am 1988;2:81-100.
44. Donabedian H, Gallin JI. The hyperimmunoglobulin E recurrentinfection (Job's) syndrome. A review of the NIH experience and the literature. Medicine (Baltimore) 1983;62:195-208.
45. Grimbacher B, Schaffer AA, Holland SM, et al. Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet 1999;65:735-744.
46. Hutto JO, Bryan CS, Greene FL, White CJ, Gallin JI. Cryptococcosis of the colon resembling Crohn's disease in a patient with the hyperimmunoglobulinemia E-recurrent infection (Job's) syndrome. Gastroenterology 1988;94:808-812.
47. Jacobs DH, Macher AM, Handler R, Bennett JE, Collen MJ, Gallin JI. Esophageal cryptococcosis in a patient with the hyperimmunoglobulin E-recurrent infection (Job's) syndrome. Gastroenterology 1984;87:201-203.
48. Borges WG, Hensley T, Carey JC, Petrak BA, Hill HR. The face of Job. J Pediatr 1998;133:303-305.
49. Smithwick EM, Finelt M, Pahwa S, et al. Cranial synostosis in Job's syndrome. Lancet 1978;1:826.
50. Hoger PH, Boltshauser E, Hitzig WH. Craniosynostosis in hyper-IgE syndrome. Eur J Pediatr 1985;144:414-417.
51. Gahr M, Muller W, Allgeier B, Speer CP. A boy with recurrent infections, impaired PMN-chemotaxis, increased IgE concentrations and cranial synostosis-a variant of the hyper-IgE syndrome? Helv Paediatr Acta 1987;42:185-190.
52. Leung DY, Key L, Steinberg JJ, et al. Increased in vitro bone resorption by monocytes in the hyperimmunoglobulin E syndrome. J Immunol 1988;140:84-88.
53. Cohen-Solal M, Prieur AM, Prin L, et al. Cytokine-mediated bone resorption in patients with the hyperimmunoglobulin E syndrome. Clin Immunol Immunopath 1995;76:75-81.
54. O'Connell AC, Puck JM, Grimbacher B, et al. Delayed eruption of permanent teeth in hyperimmunoglobulinemia E recurrent infection syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;89:177-185.
55. Bale JF Jr, Wilson JF, Hill HR. Fatal histiocytic lymphoma of the brain associated with hyperimmunoglobulinemia-E and recurrent infections. Cancer 1977;39:2386-2390.
56. Buckley R, Sampson H. The hyperimmunoglobulinemia E syndrome. In Franklin, E, editor. Clinical Immunology Update. New York: Elsevier North-Holland 1981, 147-167.
57. Gorin LJ, Jeha SC, Sullivan MP, Rosenblatt HM, Shearer WT. Burkitt's lymphoma developing in a 7-year-old boy with hyper-IgE syndrome. J Allergy Clin Immunol 1989;83:5-10.
58. Kowalchuk RM. Case of the season. Job's syndrome with superimposed lymphoma. Semin Roentgenol 1996;31:254-256.
59. Takimoto Y, Imanaka F, Nanba K. Mantle cell lymphoma associated with hyper-IgE syndrome. Rinsho Ketsueki 1996;37:1400-1404.
60. Nester TA, Wagnon AH, Reilly WF, Spitzer G, Kjeldsberg CR, Hill HR. Effects of allogeneic peripheral stem cell transplantation in a patient with job syndrome of hyperimmunoglobulinemia E and recurrent infections. Am J Med 1998;105:162-164.
61. Einsele H, Saal JG, Dopfer R, Niethammer D, Waller HD, Muller CA. Highly malignant non-Hodgkin's lymphoma in hyper-IgE syndrome. Dtsch Med Wochenschr 1990;115:1141-1144.
62. Schopfer K, Feldges A, Baerlocher K, Parisot RF, Wilhelm JA, Matter L. Systemic lupus erythematosus in Staphylococcus aureus hyperimmunoglobulinaemia E syndrome. Br Med J (Clin Res Edn) 1983;287:524-526.
63. Leyh F, Wendt V, Scherer R. Systemic lupus erythematosus and hyperIgE syndrome in a 13-year-old child. Z Hautkr 1986;61:611-614.
64. North J, Kotecha S, Holtman P, Whaley K. Systemic lupus erythematosus complicating hyper IgE syndrome. Br J Rheumatol 1997;36:297-298.
65. Brugnoni D, Franceschini F, Airo P, Cattaneo R. Discordance for systemic lupus erythematosus and hyper IgE syndrome in a pair of monozygotic twins. Br J Rheumatol 1998;37:807-808.
66. Kimata H. High-dose intravenous gamma-globulin treatment for hyperimmunoglobulinemia E syndrome. J Allergy Clin Immunol 1995;95:771-774.
67. Min JK, Cho ML, Kim SC, et al. Hyperimmunoglobulin E-recurrent infection syndrome in a patient with juvenile dermatomyositis. Korean J Intern Med 1999;14:95-98.
68. Tanji C, Yorioka N, Kanahara K, et al. Hyperimmunoglobulin E syndrome associated with nephrotic syndrome. Intern Med 1999;38:491-494.
69. Daumling S, Buriot D, Trung PH, Griscelli C, Lalama MC, Belohradsky BH. The Buckley syndrome: Recurring, severe staphylococcal infections, eczema and hyperimmunoglobulinemia E (author's translation). Infection 1980;8:248-254.
70. Van Epps DE, El Naggar A, Ochs HD. Abnormalities of lymphocyte locomotion in immunodeficiency disease. Clin Exp Immunol 1983;53:678-688.
71. - T lymphocytes in blood of hyper IgE syndrome patients. J Allergy Clin Immunol 1991;87:313.
72. Buckley RH, Becker WG. Abnormalities in the regulation of human IgE synthesis. Immunol Rev 1978;41:288-314.
73. Geha RS, Reinherz E, Leung D, McKee KT JR, Schlossman S, Rosen FS. Deficiency of suppressor T cells in the hyperimmunoglobulin E syndrome. J Clin Invest 1981;68:783-791.
74. Dreskin SC, Goldsmith PK, Gallin JI. Immunoglobulins in the hyperimmunoglobulin E and recurrent infection (Job's) syndrome. Deficiency of anti-Staphylococcus aureus immunoglobulin A. J Clin Invest 1985;75:26-34.
75. Dreskin SC, Goldsmith PK, Strober W, Zech LA, Gallin JI. Metabolism of immunoglobulin E in patients with markedly elevated serum immunoglobulin E levels. J Clin Invest 1987;79:1764-1772.
76. King CL, Gallin JI, Malech HL, Abramson SL, Nutman TB. Regulation of immunoglobulin production in hyperimmunoglobulin E recurrent-infection syndrome by interferon gamma. Proc Natl Acad Sci USA 1989;86:10085-10089.
77. Vercelli D, Jabara HH, Cunningham-Rundles C, et al. Regulation of immunoglobulin (Ig) E synthesis in the hyper-IgE syndrome. J Clin Invest 1990;85:1666-1671.
78. Paganelli R, Scala E, Capobianchi MR, et al. Selective deficiency of interferon-gamma production in the hyper-IgE syndrome. Relationship to in vitro IgE synthesis. Clin Exp Immunol 1991;84:28-33.
79. Rousset F, Robert J, Andary M, et al. Shifts in interleukin-4 and interferon-gamma production by T cells of patients with elevated serum IgE levels and the modulatory effects of these lymphokines on spontaneous IgE synthesis. J Allergy Clin Immunol 1991;87:58-69.
80. Dreskin SC, Kaliner MA, Gallin JI. Elevated urinary histamine in the hyperimmunoglobulin E and recurrent infection (Job's) syndrome: Association with eczematoid dermatitis and not with infection. J Allergy Clin Immunol 1987;79:515-522.
81. Donabedian H, Gallin JI. Mononuclear cells from patients with the hyperimmunoglobulin E-recurrent infection syndrome produce an inhibitor of leukocyte chemotaxis. J Clin Invest 1982;69:1155-1163.
82. Lin CY, Lin CC, Tang RB. Studies on hyperimmunoglobulinemia E syndrome in five children. Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi 1985;18:247-255.
83. Berger M, Kirkpatrick CH, Goldsmith PK, Gallin JI. IgE antibodies to Staphylococcus aureus and Candida albicans in patients with the syndrome of hyperimmunoglobulin E and recurrent infections. J Immunol 1980;125:2437-2443.
84. Walsh GA, Richards KL, Douglas SD, Blumenthal MN. Immunoglobulin E anti-Staphylococcus aureus antibodies in atopic patients. J Clin Microbiol 1981;13:1046-1048.
85. Ring J, Abeck D, Neuber K. Atopic eczema: Role of microorganisms on the skin surface. Allergy 1992;47:265-269.
86. Quinti I, Brozek C, Wood N, Geha RS, Leung DY. Circulating IgG autoantibodies to IgE in atopic syndromes. J Allergy Clin Immunol 1986;77:586-594.
87. Dreskin SC, Gallin JI. Evolution of the hyperimmunoglobulin E and recurrent infection (HIE, Job's) syndrome in a young girl. J Allergy Clin Immunol 1987;80:746-751.
88. Garraud O, Mollis SN, Holland SM, et al. Regulation of immunoglobulin production in hyper-IgE (Job's) syndrome. J Allergy Clin Immunol 1999;103:333-340.
89. Rabin EM, Mond JJ, Ohara J, Paul WE. Interferon-gamma inhibits the action of B cell stimulatory factor (BSF)-1 on resting B cells. J Immunol 1986;137:1573-1576.
90. Del Prete G, Tiri A, Maggi E, et al. Defective in vitro production of gamma-interferon and tumor necrosis factor-alpha by circulating T cells from patients with the hyper-immunoglobulin E syndrome. J Clin Invest 1989;84:1830-1835.
91. Borges WG, Augustine NH, Hill HR. Defective interleukin-12/interferon-gamma pathway in patients with hyperimmunoglobulinemia E syndrome. J Pediatr 2000;136:176-180.
92. Thrasher AJ, Kinnon C. The Wiskott-Aldrich syndrome. Clin Exp Immunol 2000;120:2-9.
93. Perry GS III, Spector BD, Schuman LM, et al. The Wiskott-Aldrich syndrome in the United States and Canada (1892-1979). J Pediatr 1980;97:72-78.
94. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr 1994;125:876-885.
95. Canales ML, Mauer AM. Sex-linked hereditary thrombocytopenia as a variant of Wiskott-Aldrich syndrome. N Engl J Med 1967;277:899-901.
96. Notarangelo LD, Parolini O, Faustini R, Porteri V, Albertini A, Ugazio AG. Presentation of Wiskott-Aldrich syndrome as isolated thrombocytopenia. Blood 1991;77:1125-1126.
97. Villa A, Notarangelo L, Macchi P, et al. X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat Genet 1995;9:414-417.
98. Ochs HD, Rosen FS. The Wiskott-Aldrich Syndrome. In Ochs, H D, Smith, C I E, Puck, JM, editors. Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. New York, Oxford: Oxford University Press 1999, 292-305.
99. Huntley CC, Dees SC. Eczema associated with thrombocytopenic purpura and purulent otitis media. Report of five fatal cases. Pediatrics 1957;XX:351-361.
100. Rengan R, Ochs HD. Molecular biology of the Wiskott-Aldrich syndrome. Rev Immunogenet 2000;2:243-255.
101. Cooper MD, Chae HP, Lowman JT, Krivit W, Good RA. Wiskott-Aldrich syndrome. An immunologic deficiency disease involving the afferent limb of immunity. Am J Med 1968;44:499-513.
102. Ochs HD, Slichter SJ, Harker LA, Von Behrens WE, Clark RA, Wedgwood RJ. The Wiskott-Aldrich syndrome: Studies of lymphocytes, granulocytes, and platelets. Blood 1980;55:243-252.
103. Molina IJ, Sancho J, Terhorst C, Rosen FS, Remold-O'Donnell E. T cells of patients with the Wiskott-Aldrich syndrome have a restricted defect in proliferative responses. J Immunol 1993;151:4383-4390.
104. Krivit W, Good RA. Aldrich's syndrome (thrombocytopenia, eczema, and infection in infants). Am J Dis Child 1959;97:137-153.
105. Berglund G, Finnstrom O, Johansson SGO, Moller KL. Wiskott-Aldrich syndrome. A study of 6 cases with determination of the immunoglobulins A, D, G, M and ND. Acta Paediatr Scand 1968;57:89-97.
106. Waldmann TA, Polmar SH, Balestra ST, Jost MC, Bruce RM, Terry WD. Immunoglobulin E in immunologic deficiency diseases. II. Serum IgE concentration of patients with acquired hypogammaglobulinemia, thymoma and hypogammaglobulinemia, myotonic dystrophy, intestinal lymphangiectasia and Wiskott-Aldrich syndrome. J Immunol 1972;109:304-310.
107. Belohradsky BH, Griscelli C, Fundenberg HH, Marget W. The Wiskott-Aldrich syndrome. Ergeb Inn Med Kinderheilkd 1978;41:85-184.
108. Parkman R, Rappeport J, Geha R, et al. Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone-marrow transplantation. N Engl J Med 1978;298:921-927.
109. Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994;78:635-644.
110. Zhu Q, Watanabe C, Liu T, et al. Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and pheno-type. Blood 1997;90:2680-2689.
111. Snapper SB, Rosen FS, Mizoguchi E, et al. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity 1998;9:81-91.
112. Vetrie D, Vorechovsky I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993;361:226-233.
113. Tsukada S, Saffran DC, Rawlings DJ, et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 1993;72:279-290.
114. Gerwin N, Friedrich C, Perez-Atayde A, Rosen FS, GutierrezRamos JC. Multiple antigens are altered on T and B lymphocytes from peripheral blood and spleen of patients with Wiskott-Aldrich syndrome. Clin Exp Immunol 1996;106:208-217.
115. Omenn GS. Familial reticuloendotheliosis with eosinophilia. N Engl J Med 1965;273:427-432.
116. Le Deist F, Fischer A, Durandy A, et al. Severe combined immune deficiency with hypereosinophilia. Immunologic study of 5 cases. Arch Fr Pediatr 1985;42:11-16.
117. Ochs HD, Davis SD, Mickelson E, Lerner KG, Wedgwood RJ. Combined immunodeficiency and reticuloendotheliosis with eosinophilia. J Pediatr 1974;85:463-465.
118. Gomez L, Le Deist F, Blanche S, Cavazzana-Calvo M, Griscelli C, Fischer A. Treatment of Omenn syndrome by bone marrow transplantation. J Pediatr 1995;127:76-81.
119. Villa A, Santagata S, Bozzi F, et al. Partial V(D)J recombination activity leads to Omenn syndrome. Cell 1998;93:885-896.
120. Schwarz K, Gauss GH, Ludwig L, et al. RAG mutations in human B cell-negative SCID. Science 1996;274:97-99.
121. Villa A, Sobacchi C, Notarangelo LD, et al. V(D)J recombination defects in lymphocytes due to RAG mutations: Severe immunodeficiency with a spectrum of clinical presentations. Blood 2001;97:81-88.
122. Schwarz K, Notarangelo LD, Spanopoulou E, et al. Recombination defects. In Ochs, HD, Smith, CI E, Puck, JM, editors. Primary Immunodeficiency Diseases: A Molecular and Genetic Approach. New York, Oxford: Oxford University Press 1999, 155-166.
123. Schandene L, Ferster A, Mascart-Lemone F, et al. T helper type 2-like cells and therapeutic effects of interferon-gamma in combined immunodeficiency with hypereosinophilia (Omenn's syndrome). Eur J Immunol 1993;23:56-60.
124. Chilosi M, Facchetti F, Notarangelo LD, et al. CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome: Evidence for a T helper 2-mediated condition. Eur J Immunol 1996;26:329-334.
125. Brugnoni D, Airo P, Facchetti F, et al. In vitro cell death of activated lymphocytes in Omenn's syndrome. Eur J Immunol 1997;27:2765-2773.
126. Comel M. Ichthyosis linearis circumflexa. Dermatologica 1949;98:133-136.
127. Netherton EW. A unique case of trichorrhexis nodosa-bamboo hairs. Arch Dermatol 1958;78:483-487.
128. Traupe H. The Ichthyosis. A Guide to Clinical Diagnosis, Genetic Counselling, and Therapy. Berlin: Springer 1989, 168-178.
129. Smith DL, Smith JG, Wong SW, Deshazo RD. Netherton's syndrome, a syndrome of elevated IgE and characteristic skin and hair findings. J Allergy Clin Immunol 1995;95:116-123.
130. Stevanovic DV. Multiple defects of the hair shaft in Netherton's disease. Association with ichthyosis linearis circumflexa. Br J Dermatol 1969;81:851-857.
131. Wilkinson RD, Curtis GH, Hawk WA. Netherton's disease: Trichorrhexis invaginata (bamboo hair) congenital ichthyosiform erythroderma and the atopic diathesis. A histopathologic study. Arch Derm 1964;89:46-54.
132. Fartasch M, Williams ML, Elias PM. Altered lamellar body secretion and stratum corneum membrane structure in Netherton syndrome: Differentiation from other infantile erythrodermas and pathogenic implications. Arch Dermatol 1999;135:823-832.
133. Sprecher E, Chavanas S, Digiovanna JJ, et al. The spectrum of pathogenic mutations in SPINK5 in 19 families with Netherton syndrome: Implications for mutation detection and first case of prenatal diagnosis. J Invest Dermatol 2001;117:179-187.
134. Greene SL, Muller SA. Netherton's syndrome. Report of a case and review of the literature. J Am Acad Dermatol 1985;13:329-337.
135. Chavanas S, Garner C, Bodemer C, et al. Localization of the Netherton syndrome gene to chromosome 5q32, by linkage analysis and homozygosity mapping. Am J Hum Genet 2000;66:914-921.
136. Chavanas S, Bodemer C, Rochat A, et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 2000;25:141-142.
137. Roberts RM, Mathialagan N, Duffy JY, Smith GW. Regulation and regulatory role of proteinase inhibitors. Crit Rev Eukary Gene Express 1995;5:385-436.
138. Magert HJ, Standker L, Kreutzmann P, et al. LEKTI, a novel 15-domain type of human serine proteinase inhibitor. J Biol Chem 1999;274:21499-21502.
139. Yasuda T, Ogawa M, Murata A, et al. Identification of the IL-6-responsive element in an acute-phaseresponsive human pancreatic secretory trypsin inhibitor-encoding gene. Gene 1993;131:275-280.